Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis

特应性皮炎 斯科拉德 医学 皮肤科生活质量指数 湿疹面积及严重程度指数 患者报告的结果 生活质量(医疗保健) 疾病严重程度 皮肤病科 物理疗法 内科学 护理部 银屑病
作者
Jonathan I. Silverberg,Donald Lei,Muhammad Yousaf,Sherief R. Janmohamed,Paras P. Vakharia,R. Chopra,Rajeev Chavda,Sylvie Gabriel,Kevin R. Patel,Vivek Singam,Robert Kantor,Derek Y. Hsu
出处
期刊:Annals of Allergy Asthma & Immunology [Elsevier]
卷期号:125 (1): 78-83 被引量:18
标识
DOI:10.1016/j.anai.2020.03.006
摘要

Background Little is known about the measurement properties of Patient-Oriented Scoring Atopic Dermatitis (PO-SCORAD) in adults with atopic dermatitis (AD). Even less is known about how PO-SCORAD performs compared with the Patient-Oriented Eczema Measure (POEM). Objective To examine the measurement properties of PO-SCORAD and compare them with those of POEM. Methods A prospective dermatology practice–based study of 291 patients with AD (age range, 18-72 years). Results PO-SCORAD and POEM were moderately correlated with each other (Spearman ρ = 0.56) and had weak-moderate correlations with the Numeric Rating Scale (NRS) worst itch and average itch, Dermatology Life Quality Index (DLQI), ItchyQOL, Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SD) and Sleep-Related Impairment (SRI), Patient Health Questionnaire-9 (PHQ-9), and Eczema Area and Severity Index (EASI) (P < .001). POEM had significantly stronger correlations with DLQI, ItchyQOL, and EASI than did PO-SCORAD. PO-SCORAD and POEM had fair discriminant validity. Changes from baseline in PO-SCORAD and POEM were moderately correlated with each other; were weakly to strongly correlated with NRS worst itch and average itch, DLQI, ItchyQOL, PROMIS SD, PROMIS SRI, PHQ-9, and EASI; and had good test-retest reliability. There was no differential item functioning of items or floor or ceiling effects for PO-SCORAD or POEM. The thresholds for meaningful change for PO-SCORAD and POEM were −15.5 and −5.0, respectively. Median completion times for PO-SCORAD and POEM were 3 minutes and 1 minute, respectively. Conclusion PO-SCORAD and POEM had good construct and cross-cultural validity, reliability, and responsiveness in adults with AD and were feasible for use in clinical trials and practice. However, POEM had better measurement properties than PO-SCORAD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
carl完成签到 ,获得积分10
1秒前
山君发布了新的文献求助10
3秒前
工科小白完成签到,获得积分10
4秒前
欣欣完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
13秒前
雨晴完成签到 ,获得积分10
18秒前
谦让汝燕完成签到,获得积分10
22秒前
xcwy完成签到,获得积分10
24秒前
奋斗诗云完成签到 ,获得积分10
24秒前
ntrip完成签到,获得积分10
28秒前
Panini完成签到 ,获得积分10
30秒前
缥缈的觅风完成签到 ,获得积分10
31秒前
31秒前
优雅莞完成签到,获得积分10
32秒前
jctyp完成签到,获得积分10
34秒前
yusovegoistt发布了新的文献求助10
35秒前
40秒前
41秒前
一只橘子完成签到 ,获得积分10
44秒前
科研女郎完成签到 ,获得积分10
52秒前
江江完成签到 ,获得积分10
54秒前
华仔应助山君采纳,获得10
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
小瑄完成签到 ,获得积分10
1分钟前
1分钟前
六元一斤虾完成签到 ,获得积分10
1分钟前
小宋爱科研完成签到 ,获得积分10
1分钟前
宁幼萱完成签到,获得积分10
1分钟前
neu_zxy1991完成签到,获得积分10
1分钟前
zhangj696完成签到,获得积分10
1分钟前
风清扬应助科研通管家采纳,获得10
1分钟前
顾矜应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
风清扬应助科研通管家采纳,获得10
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
风清扬应助科研通管家采纳,获得10
1分钟前
风清扬应助科研通管家采纳,获得10
1分钟前
shhoing应助科研通管家采纳,获得10
1分钟前
流星雨完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1581
以液相層析串聯質譜法分析糖漿產品中活性雙羰基化合物 / 吳瑋元[撰] = Analysis of reactive dicarbonyl species in syrup products by LC-MS/MS / Wei-Yuan Wu 1000
Biology of the Reptilia. Volume 21. Morphology I. The Skull and Appendicular Locomotor Apparatus of Lepidosauria 600
The Scope of Slavic Aspect 600
Foregrounding Marking Shift in Sundanese Written Narrative Segments 600
Rousseau, le chemin de ronde 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5539156
求助须知:如何正确求助?哪些是违规求助? 4625957
关于积分的说明 14597178
捐赠科研通 4566766
什么是DOI,文献DOI怎么找? 2503614
邀请新用户注册赠送积分活动 1481546
关于科研通互助平台的介绍 1453063